Knockdown of DRAM2 inhibits the proliferation and migration of lung cancer cell line A549

doi:10.16352/j.issn.1001-6325.2025.02.0197

Abstract

Abstract: Objective To investigate the impact of DNA damage-regulated autophagy factor 2 (DRAM2) on the proliferation and migration of non-small cell lung cancer (NSCLC) cells through tumor protein p53 (p53) and autophagy. Methods DRAM2 gene was knocked down using lentiviral technology to establish NSCLC cell lines, and autophagy markers were detected by immunofluorescence and Western blot. CCK8 and Transwell assays were used to detect cell proliferation and migration. The effects of autophagy activation and p53 knockdown on autophagy and functions of DRAM2-knockdown cells were examined. Results Knockdown of DRAM2 inhibited NSCLC cells, with upregulation of p62 expression (P＜0.05) and decreased level of LC3-Ⅱ (P＜0.05).Knockdown of DRAM2 suppressed the proliferation (P＜0.001) and migration (P＜0.001) of NSCLC cells. Activation of auto- phagy partially reversed the inhibitory effects of DRAM2 knockdown on cell proliferation (P＜0.01) and migration (P＜0.01).When DRAM2 and p53 were knocked down simultaneously, autophagy, cell proliferation (P＜0.05) and migration abilities (P＜0.001) were restored. Conclusions Knockdown of DRAM2 inhibits the proliferation and migration of lung cancer cell line A549, providing a potential intervention direction for the development of therapeutic strategies.

Key words: non-small cell lung cancer, DRAM2, p53, autophagy

CLC Number:

LOU Haijun, TONG Zhuoyun, ZHANG Zhenyu, Aheyerk·MAHESHATI, MENG·Menggen, WUDU Muli. Knockdown of DRAM2 inhibits the proliferation and migration of lung cancer cell line A549[J]. Basic & Clinical Medicine, 2025, 45(2): 197-202.

References 15

[1]	Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends[J]. Nat Rev Clin Oncol, 2023, 20: 624-639.
[2]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71: 209-249.
[3]	Li C, Lei S, Ding L, et al. Global burden and trends of lung cancer incidence and mortality[J]. Chin Med J, 2023, 136: 1583-1590.
[4]	Luo X, Wang J, Wang R, et al. Sll-1a-16 suppresses proliferation and induces autophagy in non-small-cell lung cancer cells via the AKT/mTOR signaling pathway[J]. RSC Med Chem, 2024, 15: 15:3460-3468. doi: 10.1039/d4md00405a
[5]	Wudu M, Ren H, Hui L, et al. DRAM2 acts as an oncogene in non-small cell lung cancer and suppresses the expression of p53[J]. J Exp Clin Cancer Res, 2019, 38: 72. doi:10.1186/s13046-019-1068-4.
[6]	Yamamoto H, Zhang S, Mizushima N. Autophagy genes in biology and disease[J]. Nat Rev Genet Genetics, 2023, 24: 382-400.
[7]	Koutsifeli P, Varma U, Daniels LJ, et al. Glycogen-autophagy: molecular machinery and cellular mechanisms of glycophagy[J]. J Biol Chem, 2022, 298: 102093.doi: 10.1016/j.jbc.2022.102093.
[8]	Li L, Wang X, Jiang M, et al. Advancements in a novel model of autophagy and immune network regulation in radioresistance of cancer stem cells[J]. Biomed Pharmacother, 2024, 179: 117420.doi: 10.1016/j.jbc.2022.102093.
[9]	Xia H, Green DR, Zou W. Autophagy in tumour immunity and therapy[J]. Nat Rev Cancer, 2021, 21: 281-297.
[10]	Rahman MA, Park MN, Rahman MH, et al. P53 modulation of autophagy signaling in cancer therapies: perspectives mechanism and therapeutic targets[J]. Front Cell Dev Biol, 2022, 10: 761080. doi:10.3389/fcell.2022.761080.
[11]	Xu J, Patel NH, Gewirtz DA. Triangular relationship between p53, autophagy, and chemotherapy resistance[J]. Int J Mol Sci, 2020, 21:8991. doi:10.3390/IJMS21238991.
[12]	Nahálková J. On the interface of aging, cancer, and neurodegeneration with sirt6 and l1 retrotransposon protein interaction network[J]. Ageing Res Rev, 2024: 102496. doi:10.1016/j.arr.2024.102496.
[13]	Wen W, Zhang WL, Tan R, et al. Progress in deciphering the role of p53 in diffuse large B-cell lymphoma: mechanisms and therapeutic targets[J]. Am J Cancer Res, 2024, 14: 3280-3293.
[14]	Wang H, Chen Q, Liu Q, et al. Master regulator: p53's pivotal role in steering NK-cell tumor patrol[J]. Front Immunol, 2024, 15: 1428653. doi:10.3389/fimmu.2024.1428653.
[15]	Veneziani I, Infante P, Ferretti E, et al. Nutlin-3a enhances natural killer cell-mediated killing of neuroblastoma by restoring p53-dependent expression of ligands for NKG2D and DNAM-1 receptors[J]. Cancer Immunol Res, 2021, 9: 170-183.